Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-29T10:07:27.206Z Has data issue: false hasContentIssue false
  • English
  • Français

Mrna vaccination under clozapine treatment

Published online by Cambridge University Press:  01 September 2022

P. Argitis ,
A. Karampas ,
P. Mpouras ,
O. Pikou ,
F.-E. Meintanopoulou ,
S. Karavia  and
Z. Chaviaras
P. Argitis*
Affiliation:
General Hospital of Corfu, Psychiatric, Corfu, Greece
A. Karampas
Affiliation:
General Hospital of Corfu, Psychiatric, Corfu, Greece
P. Mpouras
Affiliation:
General Hospital of Corfu, Psychiatric, Corfu, Greece
O. Pikou
Affiliation:
General Hospital of Corfu, Dermatology, Corfu, Greece
F.-E. Meintanopoulou
Affiliation:
General Hospital of Corfu, Psychiatric, Corfu, Greece
S. Karavia
Affiliation:
General Hospital of Corfu, Psychiatric, Corfu, Greece
Z. Chaviaras
Affiliation:
General Hospital of Corfu, Psychiatric, Corfu, Greece
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Common side effects are agranulocytosis and myocardiopathy. There are reports of myocardite related to m-rna vaccine for covid-19 (Pfizer-Bionteck), while the interactions with clozapine has not been yet studied.

Objectives

The object of the study is to explore the safety of COVID-19 vaccination at patients treated with clozapine.

Methods

We report a group of 27 patients from the psychiatric rehabilitation unit of the General Hospital of Corfu who were treated with clozapine and another group of 27 patients on different antipsychotic. Levels of clozapine were measured before the 1st vaccination and one month after the individuals were fully vaccinated, as well their COVID antibodies. For myocarditis detection we used CRP >1mg/dl and quadruplication of the troponin of reference.

Results

No significant difference has been observed among the 2 groups in relation to antibody production, No difference has been detected between clozapine and nor-clozapine serum levels before and after vaccination. While there was no case of myocarditis or vein embolism noticed.

Conclusions

It seems that patients treated with clozapine develop immune response to COVID-19 as individuals in any other anti-psychotic. No major side effects were reported at the two groups leading as to the conclusion that treatment with clozapine sould not be an obstacle for COVID-19 vaccination. Thus to the small number of patients in this study further research is needed.

Disclosure

No significant relationships.

Keywords

clozapinecovid
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S263
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.